Thomas D, Bello DM. Adjuvant immunotherapy for melanoma. J Surg Oncol. 2021;123:789–97. https://doi.org/10.1002/jso.26329

Article  PubMed  CAS  Google Scholar 

Stav I, Gyawali B, Goldstein DA. Duration of adjuvant immunotherapy—biologic, clinical and economic considerations. Med Oncol. 2018;35:160. https://doi.org/10.1007/s12032-018-1218-0

Article  PubMed  Google Scholar 

Weber JS, Yang JC, Atkins MB, Disis ML. Toxicities of immunotherapy for the practitioner. J Clin Oncol. 2015;33:2092–9. https://doi.org/10.1200/JCO.2014.60.0379

Article  PubMed  PubMed Central  CAS  Google Scholar 

Ritterhouse LL, Gogakos T. Molecular biomarkers of response to Cancer immunotherapy. Clin Lab Med. 2022;42:469–84. https://doi.org/10.1016/j.cll.2022.05.004

Article  PubMed  Google Scholar 

Takenaka D, Ohno Y, Koyama H, Nogami M, Onishi Y, Matsumoto K, et al. Integrated FDG-PET/CT vs. standard radiological examinations: comparison of capability for assessment of postoperative recurrence in non-small cell lung cancer patients. Eur J Radiol. 2010;74:458–64. https://doi.org/10.1016/j.ejrad.2009.03.007

Article  PubMed  Google Scholar 

Powles T, Assaf ZJ, Davarpanah N, Banchereau R, Szabados BE, Yuen KC, et al. CtDNA guiding adjuvant immunotherapy in urothelial carcinoma. Nature. 2021;595:432–7. https://doi.org/10.1038/s41586-021-03642-9

Article  PubMed  CAS  Google Scholar 

Keller L, Belloum Y, Wikman H, Pantel K. Clinical relevance of blood-based ctdna analysis: mutation detection and beyond. Br J Cancer. 2021;124:345–58. https://doi.org/10.1038/s41416-020-01047-5

Article  PubMed  Google Scholar 

Thompson JC, Yee SS, Troxel AB, Savitch SL, Fan R, Balli D, et al. Detection of therapeutically targetable driver and resistance mutations in lung Cancer patients by Next-Generation sequencing of Cell-Free Circulating tumor DNA. Clin Cancer Res. 2016;22:5772–82. https://doi.org/10.1158/1078-0432.CCR-16-1231

Article  PubMed  PubMed Central  CAS  Google Scholar 

van Ginkel JH, Huibers MMH, van Es RJJ, de Bree R, Willems SM. Droplet digital PCR for detection and quantification of Circulating tumor DNA in plasma of head and neck cancer patients. BMC Cancer. 2017;17:428. https://doi.org/10.1186/s12885-017-3424-0

Article  PubMed  PubMed Central  CAS  Google Scholar 

Yang Y, Zhang T, Wang J, Wang J, Xu Y, Zhao X, et al. The clinical utility of dynamic ctdna monitoring in inoperable localized NSCLC patients. Mol Cancer. 2022;21:117. https://doi.org/10.1186/s12943-022-01590-0

Article  PubMed  PubMed Central  CAS  Google Scholar 

Lee JH, Saw RP, Thompson JF, Lo S, Spillane AJ, Shannon KF, et al. Pre-operative ctdna predicts survival in high-risk stage III cutaneous melanoma patients. Ann Oncol. 2019;30:815–22. https://doi.org/10.1093/annonc/mdz075

Article  PubMed  PubMed Central  CAS  Google Scholar 

Henriksen TV, Tarazona N, Frydendahl A, Reinert T, Gimeno-Valiente F, Carbonell-Asins JA, et al. Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, toward assessment of adjuvant therapy efficacy and clinical behavior of recurrences. Clin Cancer Res. 2022;28:507–17. https://doi.org/10.1158/1078-0432.CCR-21-2404

Article  PubMed  CAS  Google Scholar 

Dong S, Yan B, Liu S-Y, Gao X, Hong H-Z, Li H-J, et al. Monitoring of Circulating tumor DNA and indication of De-Escalation adjuvant targeted therapy for EGFR-Mutated NSCLC after complete resection. JTO Clin Res Rep. 2025;6:100758. https://doi.org/10.1016/j.jtocrr.2024.100758

Article  PubMed  Google Scholar 

Semenkovich NP, Szymanski JJ, Earland N, Chauhan PS, Pellini B, Chaudhuri AA. Genomic approaches to cancer and minimal residual disease detection using Circulating tumor DNA. J Immunother Cancer. 2023;11:e006284. https://doi.org/10.1136/jitc-2022-006284

Article  PubMed  PubMed Central  Google Scholar 

Ignatiadis M, Sledge GW, Jeffrey SS. Liquid biopsy enters the clinic — implementation issues and future challenges. Nat Rev Clin Oncol. 2021;18:297–312. https://doi.org/10.1038/s41571-020-00457-x. (●●).

Article  PubMed  Google Scholar 

Stadler J-C, Belloum Y, Deitert B, Sementsov M, Heidrich I, Gebhardt C, et al. Current and future clinical applications of ctdna in Immuno-Oncology. Cancer Res. 2022;82:349–58. https://doi.org/10.1158/0008-5472.CAN-21-1718. (●).

Article  PubMed  CAS  Google Scholar 

Mazzeo R, Sears J, Palmero L, Bolzonello S, Davis AA, Gerratana L, et al. Liquid biopsy in triple-negative breast cancer: unlocking the potential of precision oncology. ESMO Open. 2024;9:103700. https://doi.org/10.1016/j.esmoop.2024.103700

Article  PubMed  PubMed Central  CAS  Google Scholar 

O’Sullivan HM, Feber A, Popat S. Minimal residual disease monitoring in radically treated Non-Small cell lung cancer: challenges and future directions. Onco Targets Ther 2023;16:249–59. https://doi.org/10.2147/OTT.S322242

Chung DC, Gray DM, Singh H, Issaka RB, Raymond VM, Eagle C, et al. A Cell-free DNA Blood-Based test for colorectal Cancer screening. N Engl J Med. 2024;390:973–83. https://doi.org/10.1056/NEJMoa2304714

Article  PubMed  CAS  Google Scholar 

Verschoor N, Bos MK, Oomen-de Hoop E, Martens JWM, Sleijfer S, Jager A, et al. A review of trials investigating ctDNA-guided adjuvant treatment of solid tumors: the importance of trial design. Eur J Cancer. 2024;207:114159. https://doi.org/10.1016/j.ejca.2024.114159. (●●).

Article  PubMed  CAS  Google Scholar 

Hitchen N, Shahnam A, Tie J, Circulating Tumor DNA. A Pan-Cancer biomarker in solid tumors with prognostic and predictive value. Annu Rev Med. 2025;76:207–23. https://doi.org/10.1146/annurev-med-100223-090016

Article  PubMed  CAS  Google Scholar 

Abidoye O, Ahn DH, Borad MJ, Wu C, Bekaii-Saab T, Chakrabarti S, et al. Circulating tumor DNA testing for minimal residual disease and its application in colorectal Cancer. Cells. 2025;14:161. https://doi.org/10.3390/cells14030161

Article  PubMed  PubMed Central  CAS  Google Scholar 

Abbosh C, Hodgson D, Doherty GJ, Gale D, Black JRM, Horn L, et al. Implementing Circulating tumor DNA as a prognostic biomarker in resectable non-small cell lung cancer. Trends Cancer. 2024;10:643–54. https://doi.org/10.1016/j.trecan.2024.04.004. (●).

Article  PubMed  CAS  Google Scholar 

Genta S, Araujo DV, Hueniken K, Pipinikas C, Ventura R, Rojas P, et al. Bespoke ctdna for longitudinal detection of molecular residual disease in high-risk melanoma patients. ESMO Open. 2024;9:103978. https://doi.org/10.1016/j.esmoop.2024.103978

Article  PubMed  PubMed Central  CAS  Google Scholar 

Kotani D, Oki E, Nakamura Y, Yukami H, Mishima S, Bando H, et al. Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer. Nat Med. 2023;29:127–34. https://doi.org/10.1038/s41591-022-02115-4

Article  PubMed  PubMed Central  CAS  Google Scholar 

Maddalena G, Pellatt AJ, Eluri M, Parseghian CM, Aziz K, Alfaro K, et al. INTERCEPT program of Circulating tumor DNA (ctDNA) testing for minimal residual disease (MRD) in colorectal cancer (CRC): results from a prospective clinical cohort. J Clin Oncol. 2024;42:27–27. https://doi.org/10.1200/JCO.2024.42.3_suppl.27

Article  Google Scholar 

Mittal A, Molto Valiente C, Tamimi F, Di Iorio M, Al-Showbaki L, Cescon DW, et al. Utility of ctdna in predicting relapse in solid tumors after curative therapy: a meta-analysis. JNCI Cancer Spectr. 2023;7. https://doi.org/10.1093/jncics/pkad040

Kasi PM, Aushev VN, Ensor J, Langer N, Wang CG, Cannon TL, et al. Circulating tumor DNA (ctDNA) for informing adjuvant chemotherapy (ACT) in stage II/III colorectal cancer (CRC): interim analysis of BESPOKE CRC study. J Clin Oncol. 2024;42:9–9. https://doi.org/10.1200/JCO.2024.42.3_suppl.9

Article  Google Scholar 

Tie J, Cohen JD, Lahouel K, Lo SN, Wang Y, Kosmider S, et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II Colon cancer. N Engl J Med. 2022;386:2261–72. https://doi.org/10.1056/NEJMoa2200075

Article  PubMed